vs
Side-by-side financial comparison of ENANTA PHARMACEUTICALS INC (ENTA) and UNITED SECURITY BANCSHARES (UBFO). Click either name above to swap in a different company.
ENANTA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($18.6M vs $13.5M, roughly 1.4× UNITED SECURITY BANCSHARES). UNITED SECURITY BANCSHARES runs the higher net margin — 25.2% vs -64.1%, a 89.3% gap on every dollar of revenue. On growth, UNITED SECURITY BANCSHARES posted the faster year-over-year revenue change (13.6% vs 9.8%). UNITED SECURITY BANCSHARES produced more free cash flow last quarter ($19.8M vs $-11.8M). Over the past eight quarters, ENANTA PHARMACEUTICALS INC's revenue compounded faster (4.5% CAGR vs 3.0%).
Enanta Pharmaceuticals Inc is a clinical-stage biotechnology company that develops innovative antiviral therapies for infectious diseases including hepatitis B virus, respiratory syncytial virus (RSV), and SARS-CoV-2. It operates primarily in the U.S. and global markets, partnering with pharmaceutical firms to advance its small molecule drug candidate pipeline for patients with unmet medical needs.
United Security Bancshares is a bank holding company headquartered in Fresno, California. It operates 11 branches.
ENTA vs UBFO — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $13.5M |
| Net Profit | $-11.9M | $3.4M |
| Gross Margin | — | — |
| Operating Margin | -60.5% | 31.5% |
| Net Margin | -64.1% | 25.2% |
| Revenue YoY | 9.8% | 13.6% |
| Net Profit YoY | 46.4% | 36.8% |
| EPS (diluted) | $-0.42 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.6M | $13.5M | ||
| Q3 25 | $15.1M | $14.0M | ||
| Q2 25 | $18.3M | $12.6M | ||
| Q1 25 | $14.9M | $13.7M | ||
| Q4 24 | $17.0M | $11.9M | ||
| Q3 24 | $14.6M | $13.8M | ||
| Q2 24 | $18.0M | $13.0M | ||
| Q1 24 | $17.1M | $12.8M |
| Q4 25 | $-11.9M | $3.4M | ||
| Q3 25 | $-18.7M | $4.0M | ||
| Q2 25 | $-18.3M | $2.2M | ||
| Q1 25 | $-22.6M | $2.7M | ||
| Q4 24 | $-22.3M | $2.5M | ||
| Q3 24 | $-28.8M | $3.8M | ||
| Q2 24 | $-22.7M | $4.3M | ||
| Q1 24 | $-31.2M | $4.2M |
| Q4 25 | -60.5% | 31.5% | ||
| Q3 25 | -121.6% | 40.3% | ||
| Q2 25 | -103.2% | 24.0% | ||
| Q1 25 | -164.3% | 27.5% | ||
| Q4 24 | -138.8% | 27.5% | ||
| Q3 24 | -204.4% | 37.1% | ||
| Q2 24 | -134.6% | 46.4% | ||
| Q1 24 | -192.1% | 45.9% |
| Q4 25 | -64.1% | 25.2% | ||
| Q3 25 | -123.6% | 28.7% | ||
| Q2 25 | -99.7% | 17.2% | ||
| Q1 25 | -151.7% | 19.6% | ||
| Q4 24 | -131.4% | 20.9% | ||
| Q3 24 | -197.3% | 27.7% | ||
| Q2 24 | -126.1% | 33.0% | ||
| Q1 24 | -182.7% | 32.6% |
| Q4 25 | $-0.42 | $0.18 | ||
| Q3 25 | $-0.88 | $0.23 | ||
| Q2 25 | $-0.85 | $0.13 | ||
| Q1 25 | $-1.06 | $0.16 | ||
| Q4 24 | $-1.05 | $0.14 | ||
| Q3 24 | $-1.36 | $0.22 | ||
| Q2 24 | $-1.07 | $0.25 | ||
| Q1 24 | $-1.47 | $0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $264.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $126.6M | $139.7M |
| Total Assets | $329.5M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $37.4M | $264.2M | ||
| Q3 25 | $32.3M | $211.1M | ||
| Q2 25 | $44.8M | $199.5M | ||
| Q1 25 | $60.2M | $198.4M | ||
| Q4 24 | $84.3M | $216.9M | ||
| Q3 24 | $37.2M | $216.8M | ||
| Q2 24 | $35.8M | $166.3M | ||
| Q1 24 | $63.5M | $168.6M |
| Q4 25 | $126.6M | $139.7M | ||
| Q3 25 | $64.7M | $137.4M | ||
| Q2 25 | $79.3M | $134.3M | ||
| Q1 25 | $93.5M | $132.9M | ||
| Q4 24 | $111.8M | $130.4M | ||
| Q3 24 | $128.8M | $132.9M | ||
| Q2 24 | $148.9M | $127.3M | ||
| Q1 24 | $166.1M | $124.2M |
| Q4 25 | $329.5M | $1.2B | ||
| Q3 25 | $280.7M | $1.2B | ||
| Q2 25 | $301.0M | $1.2B | ||
| Q1 25 | $323.0M | $1.2B | ||
| Q4 24 | $348.6M | $1.2B | ||
| Q3 24 | $376.7M | $1.3B | ||
| Q2 24 | $398.8M | $1.2B | ||
| Q1 24 | $413.6M | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.7M | $22.1M |
| Free Cash FlowOCF − Capex | $-11.8M | $19.8M |
| FCF MarginFCF / Revenue | -63.6% | 146.0% |
| Capex IntensityCapex / Revenue | 0.8% | 16.8% |
| Cash ConversionOCF / Net Profit | — | 6.46× |
| TTM Free Cash FlowTrailing 4 quarters | $-18.5M | $36.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.7M | $22.1M | ||
| Q3 25 | $-6.5M | $7.0M | ||
| Q2 25 | $17.5M | $8.7M | ||
| Q1 25 | $-13.5M | $3.0M | ||
| Q4 24 | $-16.8M | $19.6M | ||
| Q3 24 | $-10.4M | $5.4M | ||
| Q2 24 | $-14.8M | $2.3M | ||
| Q1 24 | $-28.6M | $7.4M |
| Q4 25 | $-11.8M | $19.8M | ||
| Q3 25 | $-7.9M | $6.1M | ||
| Q2 25 | $17.4M | $8.1M | ||
| Q1 25 | $-16.0M | $2.9M | ||
| Q4 24 | $-25.5M | $18.6M | ||
| Q3 24 | $-19.4M | $5.3M | ||
| Q2 24 | $-21.3M | $2.0M | ||
| Q1 24 | $-30.3M | $7.0M |
| Q4 25 | -63.6% | 146.0% | ||
| Q3 25 | -52.5% | 43.7% | ||
| Q2 25 | 94.7% | 64.3% | ||
| Q1 25 | -107.4% | 21.2% | ||
| Q4 24 | -150.6% | 156.0% | ||
| Q3 24 | -132.5% | 38.1% | ||
| Q2 24 | -118.6% | 15.5% | ||
| Q1 24 | -177.5% | 54.8% |
| Q4 25 | 0.8% | 16.8% | ||
| Q3 25 | 9.6% | 6.0% | ||
| Q2 25 | 0.8% | 4.6% | ||
| Q1 25 | 17.0% | 0.9% | ||
| Q4 24 | 51.6% | 8.7% | ||
| Q3 24 | 61.3% | 0.7% | ||
| Q2 24 | 36.4% | 2.2% | ||
| Q1 24 | 9.8% | 3.6% |
| Q4 25 | — | 6.46× | ||
| Q3 25 | — | 1.73× | ||
| Q2 25 | — | 4.01× | ||
| Q1 25 | — | 1.13× | ||
| Q4 24 | — | 7.87× | ||
| Q3 24 | — | 1.40× | ||
| Q2 24 | — | 0.54× | ||
| Q1 24 | — | 1.79× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
